Search research articles
Contact Us
Filters
Showing results (51-60 of 80) with videos related to
Page
of 8
Sort By:
British Journal of Pharmacology
|
March 18, 2011
Analysis of the contribution of I(to) to repolarization in canine ventricular myocardium
L Virág, N Jost, R Papp, et al.
Oncology
|
June 16, 2001
Single-agent gemcitabine is active in previously treated metastatic breast cancer
M Spielmann, A Llombart-Cussac, S Kalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie
A Ravaud, B Audhuy, F Gomez, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
July 7, 2019
Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study
Angélique Saint, J Viotti, D Borchiellini, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
July 10, 2020
Stereotactic Pelvic Reirradiation for Locoregional Cancer Relapse
R Kinj, J Doyen, J M Hannoun-Lévi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 2, 2014
Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer
I Treilleux, M Arnedos, C Cropet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 22, 2008
Prognostic factors in 1,038 women with metastatic breast cancer
R Largillier, J-M Ferrero, J Doyen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2017
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
S M Swain, M S Ewer, G Viale, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 4, 2026
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease
G Curigliano, X Hu, R Dent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 10, 2013
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial
J-Y Pierga, F-C Bidard, C Cropet, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 80) with videos related to
Sort By:
Page
of 8
British Journal of Pharmacology
|
March 18, 2011
Analysis of the contribution of I(to) to repolarization in canine ventricular myocardium
L Virág, N Jost, R Papp, et al.
Oncology
|
June 16, 2001
Single-agent gemcitabine is active in previously treated metastatic breast cancer
M Spielmann, A Llombart-Cussac, S Kalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie
A Ravaud, B Audhuy, F Gomez, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
July 7, 2019
Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study
Angélique Saint, J Viotti, D Borchiellini, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
July 10, 2020
Stereotactic Pelvic Reirradiation for Locoregional Cancer Relapse
R Kinj, J Doyen, J M Hannoun-Lévi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 2, 2014
Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer
I Treilleux, M Arnedos, C Cropet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 22, 2008
Prognostic factors in 1,038 women with metastatic breast cancer
R Largillier, J-M Ferrero, J Doyen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2017
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
S M Swain, M S Ewer, G Viale, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 4, 2026
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease
G Curigliano, X Hu, R Dent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 10, 2013
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial
J-Y Pierga, F-C Bidard, C Cropet, et al.
Page
of 8